News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
720,909 Results
Type
Article (42688)
Company Profile (439)
Press Release (677781)
Multimedia
Podcasts (90)
Webinars (16)
Section
Business (208877)
Career Advice (2025)
Deals (36047)
Drug Delivery (104)
Drug Development (83692)
Employer Resources (173)
FDA (16510)
Job Trends (15130)
News (353168)
Policy (33156)
Tag
Academia (2645)
Accelerated approval (11)
Adcomms (26)
Allergies (98)
Alliances (51105)
ALS (114)
Alzheimer's disease (1496)
Antibody-drug conjugate (ADC) (167)
Approvals (16489)
Artificial intelligence (328)
Autoimmune disease (33)
Automation (18)
Bankruptcy (373)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (122)
Biotechnology (331)
Bladder cancer (98)
Brain cancer (35)
Breast cancer (373)
Cancer (2942)
Cardiovascular disease (226)
Career advice (1694)
Career pathing (30)
CAR-T (194)
CDC (32)
Cell therapy (524)
Cervical cancer (22)
Clinical research (68670)
Collaboration (1064)
Company closure (3)
Compensation (699)
Complete response letters (27)
COVID-19 (2684)
CRISPR (64)
C-suite (338)
Cystic fibrosis (118)
Data (3041)
Decentralized trials (2)
Denatured (31)
Depression (70)
Diabetes (351)
Diagnostics (6483)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (146)
Drug pricing (130)
Drug shortages (29)
Duchenne muscular dystrophy (131)
Earnings (88699)
Editorial (44)
Employer branding (21)
Employer resources (149)
Events (117360)
Executive appointments (873)
FDA (18177)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (972)
Gene editing (141)
Generative AI (23)
Gene therapy (404)
GLP-1 (823)
Government (4592)
Grass and pollen (4)
Guidances (181)
Healthcare (19172)
HIV (42)
Huntington's disease (31)
IgA nephropathy (43)
Immunology and inflammation (163)
Immuno-oncology (8)
Indications (40)
Infectious disease (2860)
Inflammatory bowel disease (155)
Inflation Reduction Act (13)
Influenza (64)
Intellectual property (121)
Interviews (312)
IPO (16875)
IRA (47)
Job creations (3708)
Job search strategy (1436)
Kidney cancer (13)
Labor market (52)
Layoffs (525)
Leadership (19)
Legal (8007)
Liver cancer (80)
Longevity (11)
Lung cancer (413)
Lymphoma (211)
Machine learning (11)
Management (58)
Manufacturing (395)
MASH (94)
Medical device (13611)
Medtech (13616)
Mergers & acquisitions (19886)
Metabolic disorders (885)
Multiple sclerosis (99)
NASH (19)
Neurodegenerative disease (129)
Neuropsychiatric disorders (39)
Neuroscience (2212)
NextGen: Class of 2025 (6759)
Non-profit (4558)
Now hiring (47)
Obesity (451)
Opinion (237)
Ovarian cancer (103)
Pain (111)
Pancreatic cancer (121)
Parkinson's disease (193)
Partnered (22)
Patents (300)
Patient recruitment (167)
Peanut (51)
People (59085)
Pharmaceutical (86)
Pharmacy benefit managers (22)
Phase I (21585)
Phase II (30303)
Phase III (22385)
Pipeline (1654)
Policy (211)
Postmarket research (2601)
Preclinical (9272)
Press Release (67)
Prostate cancer (145)
Psychedelics (43)
Radiopharmaceuticals (272)
Rare diseases (488)
Real estate (6025)
Recruiting (67)
Regulatory (23105)
Reports (50)
Research institute (2422)
Resumes & cover letters (352)
Rett syndrome (9)
RNA editing (10)
RSV (49)
Schizophrenia (94)
Series A (168)
Series B (116)
Service/supplier (11)
Sickle cell disease (66)
Special edition (21)
Spinal muscular atrophy (153)
Sponsored (33)
Startups (3775)
State (2)
Stomach cancer (15)
Supply chain (77)
Tariffs (57)
The Weekly (57)
Vaccines (800)
Venture capital (55)
Weight loss (277)
Women's health (49)
Worklife (17)
Date
Today (69)
Last 7 days (381)
Last 30 days (1919)
Last 365 days (32063)
2025 (17184)
2024 (36302)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47417)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32186)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27994)
Location
Africa (738)
Alabama (67)
Alaska (7)
Arizona (251)
Arkansas (14)
Asia (39647)
Australia (6580)
California (7586)
Canada (2373)
China (693)
Colorado (328)
Connecticut (333)
Delaware (195)
Europe (86711)
Florida (1122)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (658)
India (26)
Indiana (365)
Iowa (18)
Japan (230)
Kansas (111)
Kentucky (30)
Louisiana (15)
Maine (64)
Maryland (1041)
Massachusetts (5734)
Michigan (248)
Minnesota (457)
Mississippi (3)
Missouri (90)
Montana (30)
Nebraska (25)
Nevada (80)
New Hampshire (70)
New Jersey (2113)
New Mexico (30)
New York (2115)
North Carolina (1148)
North Dakota (9)
Northern California (3311)
Ohio (238)
Oklahoma (16)
Oregon (38)
Pennsylvania (1628)
Puerto Rico (17)
Rhode Island (37)
South America (1112)
South Carolina (34)
South Dakota (1)
Southern California (2826)
Tennessee (126)
Texas (1142)
United States (28212)
Utah (222)
Virginia (190)
Washington D.C. (74)
Washington State (655)
West Virginia (4)
Wisconsin (70)
720,909 Results for "nuvig therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data
May 14, 2025
·
4 min read
Funding
Nuvig Ropes in $161M Series B From Big Pharma Players for Autoimmune Indications
California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, BMS and others for its Fc fragment immunomodulator aimed at improving autoimmune dysregulation.
December 5, 2024
·
1 min read
·
Kate Goodwin
Press Releases
Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator
December 5, 2024
·
4 min read
Biotech Bay
Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089
Nuvig Therapeutics, Inc. today announced the first-in-human dosing of NVG-2089, a proprietary product being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune disease.
February 12, 2024
·
2 min read
Business
Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer
Nuvig Therapeutics, Inc., a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer.
October 4, 2023
·
2 min read
Business
Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer
Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, announced the appointment of Julie Anne Smith as Chief Executive Officer and member of the Board of Directors.
January 4, 2023
·
2 min read
Press Releases
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
July 3, 2025
·
7 min read
Business
Nuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer
Nuvig Therapeutics, Inc. announced today the appointment of Joanne Quan, M.D., as Chief Medical Officer.
August 15, 2022
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Biotech Bay
Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases
Nuvig Therapeutics, Inc. , announced today the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function.
May 11, 2022
·
3 min read
1 of 72,091
Next
